Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.69 |
| ▸ | TTR | P02766 | 2/20 | 0.69 |
| ▸ | MMP2 | P08253 | 3/20 | 0.69 |
| ▸ | MMP9 | P14780 | 3/20 | 0.69 |
| ▸ | MMP8 | P22894 | 2/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | TYR | P14679 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15298268 | 0.88 | TTR (0.59) | APPTTRMMP2MMP9MMP8 | |
| SCHEMBL14898162 | 0.85 | TTR (0.74) | APPTTRMMP2MMP9MMP8 | |
| SCHEMBL16832047 | 0.85 | TTR (0.56) | APPTTRMMP2MMP9MMP8 | |
| SCHEMBL16831805 | 0.85 | TTR (0.56) | APPTTRMMP2MMP9MMP8 | |
| SCHEMBL16831807 | 0.85 | TTR (0.56) | APPTTRMMP2MMP9MMP8 | |
| SCHEMBL16832048 | 0.85 | TTR (0.56) | APPTTRMMP2MMP9MMP8 | |
| SCHEMBL13663908 | 0.84 | MMP9 (0.76) | APPMMP2MMP9MMP8NFKB1 | |
| Plicatin B SCHEMBL1227605 | 0.83 | AKR1C3 (0.73) | APPTTRMMP2NFKB1PTPN1 | |
| SCHEMBL28553083 | 0.83 | APP (0.62) | APPTTRMMP2MMP9MMP8 | |
| SCHEMBL12593153 | 0.83 | IAPP (0.67) | APPTTRMMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
| US-20160279084-A1 | TARGETED TREATMENT OF ANEROBIC CANCER | UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | APP 653/4885TTR 1566/4885MMP2 586/4885 |
| US-20160279084-A1 | TARGETED TREATMENT OF ANEROBIC CANCER | SLC16A3, SLC16A1, SLC16A7 | APP 4806/4885TTR 1929/4885MMP2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.